Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

93 Percent of Nucleoside-Naive Chronic Hepatitis B e-Antigen (HBeAg)-Negative Patients Achieved Undetectable Viral Load by Week 48 of Re-Treatment

PRINCETON, N.J., April 13, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced data from a cohort of nucleoside-naive HBeAg-negative chronic hepatitis B patients (ETV-027/901, n=99). These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption of treatment with BARACLUDE(R) (entecavir) achieved viral suppression and liver enzyme (ALT) normalization when re- treated for 48 weeks with BARACLUDE. The study results were presented at the 42nd Annual Meeting of the European Association for the Study of Liver Diseases (EASL) in Barcelona, Spain.

In this cohort, 93 percent of patients who were re-treated with BARACLUDE had undetectable viral load - the level of the hepatitis B virus in the blood - (HBV DNA <300 copies/mL, measured by a common assay - polymerase chain reaction or PCR) and 83 percent achieved liver enzyme normalization (ALT less than or equal to 1xULN) after 48 weeks of therapy.

"This study showed that when treated again with BARACLUDE for 48 weeks, patients achieved responses similar to those seen prior to treatment interruption, with safety results consistent with previously reported experience," said Hakan Senturk, MD, of the Ist.Univ.Cerrahpasa Tip Fak, Istanbul, Turkey.

No deaths or treatment discontinuations due to adverse events were reported in this cohort. The most common adverse events occurring in greater than 10 percent of patients were abdominal pain, fatigue, upper respiratory tract infection, nasopharyngitis, increased ALT, arthralgia, and headache.

About the Nucleoside-Naive HBeAg-Negative BARACLUDE(R) (entecavir) Re- Treatment Cohort

This analysis evaluated BARACLUDE(R) (entecavir) in nucleoside-naive chronic HBeAg-negative patie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
(Date:8/28/2015)... 28, 2015  With the heroin epidemic in ... Jacksonville -based Lakeview Health drug and ... helping to explain why fentanyl is causing a new ... 50 times more potent than pharmaceutical grade heroin and ... the risk of death skyrockets. "Fentanyl can ...
(Date:8/28/2015)... 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical company ... announced the filing of a registration statement on Form ... relating to a proposed initial public offering of its ... and the price range for the offering have not ... stock under the symbol "CTMX" on the NASDAQ Global ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2
... presented at 12th Congress of European Hematology ... -- Alexion,Pharmaceuticals, Inc. today announced results from ... (eculizumab) for the,treatment of paroxysmal nocturnal hemoglobinuria ... organized by The European,Hematology Association (EHA) in ...
... over Placebo Larger at One Year than at ... 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that the,benefits ... 2 study in mild-to- moderate Alzheimer's,disease were statistically ... Importantly, on every endpoint studied, the benefits,of Dimebon ...
Cached Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6
(Date:8/31/2015)... TX (PRWEB) , ... August 31, 2015 , ... ... EARLIER Awareness campaign, TAKE ACTION. NOT CHANCES. (SM) will be featured on a ... The eye-catching campaign image is designed to inspire and promote earlier awareness of ...
(Date:8/31/2015)... Ann Arbor, Michigan (PRWEB) , ... August 31, ... ... writes standards, and tests and certifies products for the water, food, health sciences ... as complying with NSF/ANSI 61 for their advanced iron filtration media, Pro-OX Manganese ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... ... 30, 2015 , ... ProTrailer Party is a new and exciting set of ... styled and detailed presets, allowing FCPX users to immerse the audience into the party. ... film makers save time while adding professional titles to every project. , ProTrailer Party ...
(Date:8/30/2015)... ... ... Negotiating an FDA Import Hold Crisis:, Strategies for Challenging FDA Findings, **FDAnews ... , US authorities are holding imports more than ever before, particularly at ports that ... an uptick and a new final rule, having a top-notch import compliance program is ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3
... for,Protective Coatings is pleased to announce that the ... of certification credits,for industrial hygienists who pass the ... Refresher (C-5) training courses. ABIH is a non-profit,professional ... of industrial hygiene and is the certifying organization ...
... House Science and Technology Committee for Holding Health IT ... ... IT Now!,Coalition, co-chaired by former Sen. John Breaux and former Rep. Nancy,Johnson, ... session. "It,s time for Congress to act so that our health ...
... ) announced today the final tabulation of votes at its,Annual Meeting ... -- Shareholders voted to adopt the merger agreement with ... to approve the merger agreement. Approval ... vote of a majority of shares voting on this ...
... SEIU United Healthcare,Workers-West and SEIU Local ... stop Tenet Healthcare Corp. from cutting health ... registered nurses,pharmacists, licensed vocational nurses, respiratory care ... Workers represented by the two unions ...
... Ramps ... Million, CHICAGO, Sept. 26 Since its launch in April, more ... and have lost more than three-quarters of a million pounds.,Challenge founder Dr. ... will lead the way to a million pounds lost by the,final stop ...
... tension, ... avoid tissue damage, ANDOVER, Mass., Sept. 26 Smith ... launch of the,KINSA RC 5.5 Suture Anchor, designed to provide secure repair ... of muscles,and tendons that control shoulder motion. Surgeons can repair these ...
Cached Medicine News:Health News:ABIH Approves Certification Credit for SSPC Training Courses 2Health News:Health IT Now! Coalition Calls on Congress to Pass Health Information Technology Legislation This Year 2Health News:Arrow International Announces Annual Meeting Voting Results 2Health News:Unions File Charges Against Tenet Healthcare Corporation 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 2Health News:The Challenge: Make It A Million (Pounds Lost That Is) 3Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 2Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 3Health News:Smith & Nephew Endoscopy's KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries 4
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: